Hypoxia-inducible factors: mediators of cancer progression and targets for cancer therapy

被引：1232

作者：

Semenza, Gregg L. ^{[1
,2
,3
,4
,5
,6
]}

机构：

[1] Johns Hopkins Univ, Sch Med, Vasc Program, Inst Cell Engn, Baltimore, MD 21205 USA

[2] Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD 21205 USA

[3] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA

[4] Johns Hopkins Univ, Sch Med, Dept Radiat Oncol, Baltimore, MD 21205 USA

[5] Johns Hopkins Univ, Sch Med, Dept Biol Chem, Baltimore, MD 21205 USA

[6] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD 21205 USA

来源：

TRENDS IN PHARMACOLOGICAL SCIENCES | 2012年 / 33卷 / 04期

关键词：

RENAL-CELL CARCINOMA; GROWTH-FACTOR RECEPTOR; BREAST-CANCER; UP-REGULATION; TRANSCRIPTIONAL ACTIVITY; INDUCED CHEMORESISTANCE; DOWN-REGULATION; HIF-BINDING; STEM-CELLS; E-CADHERIN;

D O I：

10.1016/j.tips.2012.01.005

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Hypoxia-inducible factors (HIFs) mediate adaptive physiological responses to hypoxia. In human cancers that are accessible for O-2 electrode measurements, intratumoral hypoxia is common and severe hypoxia is associated with increased risk of mortality. HIF activity in regions of intratumoral hypoxia mediates angiogenesis, epithelial-mesenchymal transition, stem-cell maintenance, invasion, metastasis, and resistance to radiation therapy and chemotherapy. A growing number of drugs have been identified that inhibit HIF activity by a variety of molecular mechanisms. Because many of these drugs are already FDA-approved for other indications, clinical trials can (and should) be initiated to test the hypothesis that incorporation of HIF inhibitors into current standard-of-care therapy will increase the survival of cancer patients.

引用

页码：207 / 214

页数：8

共 91 条

[1]

[Anonymous], 2011, Cancer Facts and Figures 2011

[2]

Assinder EW, 1936, LANCET, V1, P304

[3] Spermidine/spermine N1-acetyltransferase-1 binds to hypoxia-inducible factor-1α (HIF-1α) and RACK1 and promotes ubiquitination and degradation of HIF-1α [J].